A targeting strategy assisted by mathematical models is being evaluated in 128 patients with Parkinson’s disease. The PARKEO 2 trial aims to determine whether this method helps to better position deep brain stimulation electrodes while limiting the risks associated with stimulating surrounding tissues. Its results are expected on October 1 , 2026, in Marseille.
Targeting accurate to within a few millimeters
Deep brain stimulation involves implanting electrodes in deep brain regions, such as the subthalamic nucleus or the globus pallidus. For some patients, it can alleviate tremors and dyskinesias. However, choosing the electrode placement is a delicate matter: anatomical differences between individuals and the proximity of surrounding tissues can affect the treatment’s effectiveness and its side effects.
High-field magnetic resonance imaging, tractography, and other visualization techniques allow for better observation of the brain structures involved. However, as Professor Jean Régis, head of the functional neurosurgery department at La Timone Hospital in Marseille, points out, the challenge is to identify the clinical « sweet spot, » that is, the area offering the best compromise between efficacy and safety.
Imaging data to guide planning
The French start-up Rebrain is developing a method based on imaging data and clinical information gathered from patients who have already undergone surgery. Anatomical landmarks are identified on MRIs, then supervised mathematical models analyze the differences between patients and suggest an area of interest to the surgeon.
This proposal aims to assist in target selection; the source does not present it as a replacement for the surgeon’s decision. Rebrain, created in 2021, is based on a decade of research conducted at the Bordeaux University Hospital and with Inria.
A trial involving 128 patients
The strategy is being evaluated in PARKEO 2, a multicenter, randomized trial involving 128 people with Parkinson’s disease. It compares the targeting proposed by this approach to that typically used in participating centers. The study examines its efficacy and accuracy, as well as its safety and implications for patients, surgical teams, and the healthcare system, with a one-year evaluation.
According to information published on September 28, 2026, the results are to be presented on October 1 at a symposium during the WSSFN 2026 congress in Marseille, prior to scientific publication. They are therefore not yet available at that time.
Applications envisioned beyond Parkinson’s
If the results are favorable, the technology could be deployed and studied for other functional neurosurgical indications, including essential tremor. Rebrain also indicates that it is developing models for targeting the globus pallidus internus, among other conditions, for dystonia. These applications remain to be evaluated.
In France, more than 270,000 people live with Parkinson’s disease, according to figures cited by Futura. This number could double by 2050.
Source: Health: the latest news from Futura (www.futura-sciences.com)
Original article: See the original source
Author: Thibault Caudron, Journalist
